| Similar Articles |
|---|
 |
The Motley Fool
May 5, 2006
Stephen D. Simpson |
FoxHollow-ed Out Worries about guidance may be giving investors a second crack at this med-tech stock.   |
The Motley Fool
February 27, 2006
Stephen D. Simpson |
A Foxy Idea? Medical device maker Foxhollow is in an attractive niche, but management turnover is a reason for investors to worry. |
The Motley Fool
May 4, 2007
Billy Fisher |
In Search of New Prey at FoxHollow The medical device maker reported a 6% increase in revenues on a year-over-year basis for its first-quarter. Investors, take note. |
The Motley Fool
July 5, 2006
Glenn Brandys |
FoxHollow's SilverHawk Won't Soar Cost, time, and competition are holding back the med-tech's device for treating artery disease. Investors, take note. |
BusinessWeek
June 20, 2005
Spencer E. Ante |
Powering Through Clogged Arteries FoxHollow's SilverHawk is a promising alternative to stents and bypass surgery. |
The Motley Fool
February 15, 2007
Billy Fisher |
Taking FoxHollow's Pulse The medical-device maker gets a checkup from the market. Results were mixed, although the stock was trading down 4%. |
The Motley Fool
July 26, 2006
Stephen D. Simpson |
Aspect Gives Investors Nightmares The med tech company continues to grow, but high volatility is likely to follow. |
The Motley Fool
September 29, 2006
Brian Lawler |
Merck Likes FoxHollow The pharmaceutical giant signs another collaborative research agreement with the small-cap company. Investors, take note. |
The Motley Fool
December 29, 2006
Matthew Crews |
FoxHollow: Scale Is Critical Can this medical-device maker be a long-term success, or is it just a one-hit wonder? Investors, take note. |
The Motley Fool
June 30, 2006
Stephen D. Simpson |
Arrow's Erratic Flight Progress for the med-tech is still slow in coming, though market rewards have come faster. Investors, take note. |
The Motley Fool
January 25, 2006
Stephen D. Simpson |
Abbott Wins No matter what Boston Scientific does with Guidant, Abbott looks like a winner. This stock might not offer a rocket ride the way smaller biotechs and med-tech companies do, but at today's prices, at least you won't have to worry about a fiery re-entry. |
The Motley Fool
February 5, 2007
Ryan Fuhrmann |
Boston Scientific's Unscientific Outlook There's still uncertainty as the med-tech company blends an acquisition and deals with controversy. Investors, take note. |
The Motley Fool
November 15, 2005
Stephen D. Simpson |
Guidant, J&J Kiss and Make Up The two companies hammered out a revised merger agreement that continues J&J's buyout of Guidant, but at a lower price. So what does this mean for the med-tech space, assuming that this deal actually goes through? Investors, take note. |
The Motley Fool
January 30, 2006
Stephen D. Simpson |
A Bard's Tale The advanced medical technology company's stock already reflects new products' potential. Still, life in the med-tech sector could get more interesting in the coming quarters. Investors, take note. |
The Motley Fool
May 4, 2006
Stephen D. Simpson |
Aspect Won't Put You to Sleep High valuation of this med-tech company all but guarantees that the stock will see some volatility. |
The Motley Fool
November 10, 2006
Billy Fisher |
FoxHollow Taken to the Cleaners The medical-device maker's reduced guidance leaves investors steamed. |
The Motley Fool
August 23, 2006
Stephen D. Simpson |
Is Medtronic Sweeping the Deck? Nothing's changing at a deep fundamental level in health care that would impede the growth of this giant med-tech corporation. However, investors need to proceed with caution. |
The Motley Fool
February 21, 2007
Billy Fisher |
Scorching Sales Growth at ev3 Profits should be arriving soon for this medical device maker. The medical breakthroughs already are. Investors, take note. |
The Motley Fool
April 21, 2006
Stephen D. Simpson |
Bard Rolls On Nothing flashy here, but at the right price, this would be an interesting med-tech play. Investors, take note. |
The Motley Fool
May 9, 2005
Stephen D. Simpson |
Integra LifeSciences Strikes a Nerve The med-tech company's missed quarter coupled with some slightly disappointing guidance caused investors to lose a bit of faith, sending the shares down more than 15% at one point. |
The Motley Fool
November 9, 2006 |
FoxHollow Technologies: Fool by Numbers The med-tech company released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
August 21, 2006
Stephen D. Simpson |
Kensey Nash Losing the Benefit of the Doubt Med-tech investors won't wait indefinitely for growth. Investors can find better values in this sector if they're willing to roll up their sleeves for some due diligence. |
